|Print This Page Email to a Friend|
Read Dr. Usmani's full editorial.
Saad Usmani, MD, FACP, Director of the Plasma Cell Disorders program and director of clinical research in hematologic malignancies at Levine Cancer Institute, had an editorial published in Informa HealthCare, that discusses the implications of current research underway for asymptomatic multiple myeloma.
Dr. Usmani’s review titled, “How long can we let the myeloma smolder?” evaluates a key study published in the New England Journal of Medicine-- “Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma,” (Mateos MV, Hernandez MT, Giraldo P, et al.)
Included in Dr. Usmani’s ediorital are the following key takeaways: